Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients

Bevacizumab is a humanized anti-VEGF monoclonal antibody able to produce clinical benefit in advanced non-squamous non-small-cell lung cancer (NSCLC) patients when combined to chemotherapy. At present, while there is a rising attention to bevacizumab-related adverse events and costs, no clinical or...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Botta, Cirino, Barbieri, Vito, Ciliberto, Domenico, Rossi, Antonio, Rocco, Danilo, Addeo, Raffaele, Staropoli, Nicoletta, Pastina, Pierpaolo, Marvaso, Giulia, Martellucci, Ignazio, Guglielmo, Annamaria, Pirtoli, Luigi, Sperlongano, Pasquale, Gridelli, Cesare, Caraglia, Michele, Tassone, Pierfrancesco, Tagliaferri, Pierosandro, Correale, Pierpaolo
Format: Artigo
Idioma:Inglês
Publicat: Landes Bioscience 2013
Matèries:
Bedside to Bench Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3813562/
https://ncbi.nlm.nih.gov/pubmed/23760488
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.24425
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars